Oxaliplatin Accord

Oxaliplatin, the active ingredient in Oxaliplatin Accord, is a platinum‑based chemotherapy presented as a solution for intravenous use. It is employed in the treatment of colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Accord is a platinum‑based chemotherapeutic agent used primarily within the colorectal cancer treatment pathway.

- Colorectal cancer: Enhances tumor response when combined with fluoropyrimidine‑based regimens. - Gastric cancer: Contributes to disease control as part of combination chemotherapy. - Pancreatic cancer: Used in select protocols to improve progression‑free survival. - Ovarian cancer: Provides additional cytotoxic activity in platinum‑sensitive disease. - Esophageal cancer: Integrated into multimodal regimens for locally advanced disease.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, requiring careful monitoring during therapy.

Common Side Effects: - Nausea and vomiting: Frequent gastrointestinal upset during infusion. - Peripheral neuropathy: Tingling or numbness, often dose‑dependent. - Diarrhea: May range from mild to moderate severity. - Fatigue: Generalized tiredness experienced by many patients. - Myelosuppression: Decreased blood cell counts, increasing infection risk. - Elevated liver enzymes: Transient rise in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: Anaphylaxis or bronchospasm during infusion. - Acute neurotoxicity: Sudden onset of muscle cramps or jaw tightness. - Thrombotic microangiopathy: Rare clotting disorder affecting small vessels.\n- Hemolytic‑urine  .

Oxaliplatin should be administered  ​  ​  ​   g   g  d   ewline   ewline  ewline  ewline  lank \

The    t